Production (Stage)
Verve Therapeutics, Inc.
VERV
$4.36
-$0.02-0.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 152.11% | 90.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 152.11% | 90.53% | |||
| Cost of Revenue | -1.07% | 10.23% | |||
| Gross Profit | 48.81% | 2.57% | |||
| SG&A Expenses | 7.48% | 1.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.67% | 8.42% | |||
| Operating Income | 34.66% | 1.48% | |||
| Income Before Tax | 38.04% | 0.13% | |||
| Income Tax Expenses | 8.22% | -29.81% | |||
| Earnings from Continuing Operations | 37.98% | 0.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.98% | 0.20% | |||
| EBIT | 34.66% | 1.48% | |||
| EBITDA | 35.77% | 1.43% | |||
| EPS Basic | 39.31% | 2.79% | |||
| Normalized Basic EPS | 39.37% | 2.73% | |||
| EPS Diluted | 39.31% | 2.79% | |||
| Normalized Diluted EPS | 39.37% | 2.73% | |||
| Average Basic Shares Outstanding | 2.21% | 2.65% | |||
| Average Diluted Shares Outstanding | 2.21% | 2.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||